Now that the analysis of Pfizer’s postmarketing trial for Xeljanz is complete, though, application reviews of other products will likely be completed. The Xelijanz study revealed elevated risk of heart-related events, cancer, blood clots and death, resulting in a class-wide indication restriction and a revised boxed warning.
Cardiovascular, cancer and other concerns forced the US Food and Drug Administration to limit the use of several JAK inhibitors to patients who cannot tolerate one or more TNF blockers.
Based on a review of safety data on Pfizer Inc.’s rheumatoid arthritis and ulcerative colitis drugs Xeljanz and Xeljanz...